Intriguingly, emapalumab, a monoclonal antibody targeting IFN-γ, has been tested in COVID-19 patients, starting from the positive results in hemophagocytic lymphohistiocytosis (HLH), a condition with elevated serum levels of IFN-γ, which leads to cytokine storm as it occurs during COVID-19 [77]. The gene discussed is IFNG; the disease is hemophagocytic syndrome.